GGTI 2147
Code | Size | Price |
---|
TAR-T25450-1mg | 1mg | £488.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T25450-5mg | 5mg | £1,010.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T25450-10mg | 10mg | £1,299.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T25450-25mg | 25mg | £1,661.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T25450-50mg | 50mg | £1,982.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T25450-100mg | 100mg | £2,560.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
GGTI 2147 is an inhibitor of protein geranylgeranyltransferase-I and protein prenylation which increases prelamin A accumulation by suppressing ZMPSTE24 protein in human fibroblast and improves cytosolic accumulation of Rac1 and elicits significant inhibition of GSIS from INS 832/13 cells.
CAS:
191102-87-1
Formula:
C28H30N4O3
Molecular Weight:
470.573
Pathway:
Cell Cycle/Checkpoint|NF-κb
Purity:
0.98
SMILES:
COC(=O)[C@H](CC(C)C)NC(=O)c1ccc(NCc2c[nH]cn2)cc1-c1cccc2ccccc12
Target:
NF-κB|Rho
References
1. Yuan M, Gao S, Sun C, Chen L, Shi Q, Hu J, Yu R, Zhou X. Inhibiting geranylgeranyltransferase I activity decreases spine density in central nervous system. Hippocampus. 2015 Mar;25(3):373-84. doi: 10.1002/hipo.22379. Epub 2014 Nov 25. PubMed PMID: 25330763.
2. Appels NM, Bolijn MJ, van Eijndhoven MA, Stephens TC, Beijnen JH, Schellens JH. Characterization of the in vitro activity of AZD3409, a novel prenyl transferase inhibitor. Cancer Chemother Pharmacol. 2011 Jan;67(1):137-45. doi: 10.1007/s00280-010-1300-6. Epub 2010 Mar 13. PubMed PMID: 20229082.
3. Subasinghe W, Syed I, Kowluru A. Phagocyte-like NADPH oxidase promotes cytokine-induced mitochondrial dysfunction in pancreatic ?-cells: evidence for regulation by Rac1. Am J Physiol Regul Integr Comp Physiol. 2011 Jan;300(1):R12-20. doi: 10.1152/ajpregu.00421.2010. Epub 2010 Oct 13. PubMed PMID: 20943855; PubMed Central PMCID: PMC3023281.
4. Okamoto S, Jiang Y, Kawamura K, Shingyoji M, Tada Y, Sekine I, Takiguchi Y, Tatsumi K, Kobayashi H, Shimada H, Hiroshima K, Tagawa M. Zoledronic acid induces apoptosis and S-phase arrest in mesothelioma through inhibiting Rab family proteins and topoisomerase II actions. Cell Death Dis. 2014 Nov 13;5:e1517. doi: 10.1038/cddis.2014.475. PubMed PMID: 25393473; PubMed Central PMCID: PMC4260733.